Gain Therapeutics (NASDAQ:GANX) Rating Reiterated by Oppenheimer

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “outperform” rating reissued by stock analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock. Oppenheimer’s price target indicates a potential upside of 182.13% from the company’s previous close.

A number of other brokerages have also recently commented on GANX. Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, March 27th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Monday, April 1st.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX opened at $3.19 on Tuesday. The stock has a market capitalization of $51.74 million, a price-to-earnings ratio of -1.87 and a beta of 0.43. Gain Therapeutics has a 12 month low of $2.00 and a 12 month high of $5.65. The firm’s 50 day simple moving average is $4.04 and its 200-day simple moving average is $3.44. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.59 and a quick ratio of 3.59.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. Analysts expect that Gain Therapeutics will post -1.17 EPS for the current year.

Insider Activity at Gain Therapeutics

In related news, Director Jeffrey Scott Riley purchased 30,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, with a total value of $115,800.00. Following the purchase, the director now owns 30,000 shares of the company’s stock, valued at $115,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.00% of the stock is owned by corporate insiders.

About Gain Therapeutics

Gain Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies.